Treatment of Catheter-Related Bloodstream Infections

Empirical Antibiotic Therapy

• The Infectious Diseases Society of America recommends vancomycin as the cornerstone of empirical therapy in healthcare settings with elevated MRSA prevalence 1
• For institutions where MRSA isolates have vancomycin MIC values >2 μg/mL, the Infectious Diseases Society of America suggests using alternative agents such as daptomycin instead 1
• The Infectious Diseases Society of America advises against using linezolid for empirical therapy in patients suspected but not proven to have bacteremia 1
• In units with low MRSA prevalence, the Infectious Diseases Society of America recommends cefazolin as a substitute for vancomycin 2, 3
• The Infectious Diseases Society of America recommends basing empirical gram-negative coverage on local antimicrobial susceptibility data and disease severity 1
• The Infectious Diseases Society of America suggests using fourth-generation cephalosporins, carbapenems, or β-lactam/β-lactamase combinations, with or without aminoglycosides, for gram-negative coverage 1
• For neutropenic patients, severely septic patients, or those colonized with multidrug-resistant organisms, the Infectious Diseases Society of America recommends using empirical combination therapy for Pseudomonas aeruginosa until culture results allow de-escalation 1
• The Infectious Diseases Society of America recommends adding coverage for gram-negative bacilli and Candida species in addition to gram-positive coverage for femoral catheters in critically ill patients 1
• The Infectious Diseases Society of America suggests using empirical antifungal therapy for septic patients with risk factors including total parenteral nutrition, prolonged broad-spectrum antibiotics, hematologic malignancy, transplant recipients, femoral catheterization, or multi-site Candida colonization 1

Catheter Management

• The Infectious Diseases Society of America recommends catheter removal in cases of severe sepsis or hemodynamic instability 4, 5
• The Infectious Diseases Society of America suggests catheter removal in cases of persistent bacteremia despite appropriate antibiotics 4, 5
• The Infectious Diseases Society of America recommends catheter removal in cases of complicated infections, including septic thrombosis, endocarditis, or metastatic infection 4, 6
• The Infectious Diseases Society of America advises catheter removal in cases of tunnel or exit-site infection with purulence 4
• The Infectious Diseases Society of America recommends catheter removal in cases of infections caused by S. aureus, Candida species, Pseudomonas (non-aeruginosa), Bacillus, Corynebacterium, or mycobacteria 4, 5

Pathogen-Specific Treatment Duration

• The Infectious Diseases Society of America recommends performing transesophageal echocardiography (TEE) in patients without contraindications to identify complicating endocarditis in cases of S. aureus bacteremia 4, 7
• The Infectious Diseases Society of America suggests 14 days of therapy for uncomplicated bacteremia with catheter removal and negative TEE 4, 5
• The Infectious Diseases Society of America recommends 4-6 weeks of therapy for complicated infection or positive TEE 4, 5
• The Infectious Diseases Society of America defines day 1 of therapy as the first day with negative blood cultures 1
• The Infectious Diseases Society of America recommends 10-14 days of appropriate antimicrobial therapy for nontunneled catheters with catheter removal in cases of gram-negative bacilli 4, 5
• The Infectious Diseases Society of America suggests considering catheter removal, especially if bacteremia persists or the patient becomes unstable, in cases of Pseudomonas species (other than P. aeruginosa), Burkholderia cepacia, Stenotrophomonas, Agrobacterium, or Acinetobacter baumannii 4, 5
• The Infectious Diseases Society of America recommends removing all tunneled catheters or implantable devices in cases of documented fungemia due to Candida species 4, 5
• The Infectious Diseases Society of America suggests using amphotericin B for hemodynamically unstable patients or those with prolonged fluconazole exposure in cases of Candida species 4, 5
• The Infectious Diseases Society of America recommends fluconazole for stable patients without recent fluconazole therapy and susceptible organisms in cases of Candida species 4, 5
• The Infectious Diseases Society of America suggests using echinocandins (caspofungin, micafungin, or anidulafungin) as preferred empirical therapy in cases of Candida species 2, 3

Antibiotic Lock Therapy

• The Infectious Diseases Society of America recommends vancomycin 2.5-5.0 mg/mL (5.0 mg/mL more efficacious for biofilm eradication) as a lock concentration for antibiotic lock therapy 2, 3
• The Infectious Diseases Society of America suggests cefazolin 5.0 mg/mL for methicillin-susceptible staphylococci as a lock concentration for antibiotic lock therapy 2, 3
• The Infectious Diseases Society of America recommends gentamicin 1.0 mg/mL for gram-negative organisms as a lock concentration for antibiotic lock therapy 2, 3
• The Infectious Diseases Society of America suggests ceftazidime 0.5 mg/mL for gram-negative organisms as a lock concentration for antibiotic lock therapy 2, 3
• The Infectious Diseases Society of America recommends ciprofloxacin 0.2 mg/mL for gram-negative organisms as a lock concentration for antibiotic lock therapy 2, 3
• The Infectious Diseases Society of America suggests 70% ethanol lock for mixed infections as a lock concentration for antibiotic lock therapy 2, 3

Hemodialysis Patients

• The Infectious Diseases Society of America recommends vancomycin 20 mg/kg loading dose during last hour of dialysis, then 500 mg during last 30 minutes of each subsequent session, plus gentamicin 1 mg/kg (max 100 mg) after each dialysis session, or ceftazidime 1 g IV after each session, as an empirical regimen for hemodialysis patients 2, 3

Catheter Management and Treatment of Acinetobacter baumannii Bacteremia

Catheter Removal Indications

• In any patient with confirmed A. baumannii bacteremia, the intravascular catheter should be removed immediately because the organism is among the pathogens that mandate catheter extraction (e.g., Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas spp.) 8.
• Catheter removal is also required when bacteremia persists despite appropriate antimicrobial therapy or when the patient remains hemodynamically unstable 8.
• Catheter salvage strategies are not recommended for A. baumannii infections; the infected catheter must be removed [8][9].

Antimicrobial Therapy Duration After Catheter Removal

• For patients whose catheter has been removed (including non‑tunneled catheters), a 10–14‑day course of appropriate antimicrobial therapy should be administered following removal 8.
• In cases of prolonged bacteremia—particularly when underlying valvular heart disease is present—4–6 weeks of antibiotic treatment is advised after catheter removal and initiation of suitable therapy 8.

Management of Persistent Bacteremia and Complications

• If bacteremia persists for ≥72 hours despite appropriate antimicrobial therapy, an aggressive evaluation for complications (e.g., septic thrombosis, infective endocarditis, metastatic infection) is warranted 10.
• Systematic investigation for septic thrombosis, infective endocarditis, and other metastatic foci should be performed in the setting of persistent bacteremia 10.

Septic Thrombophlebitis

• Septic thrombophlebitis should be suspected when bacteremia continues 3 days after catheter removal and appropriate antimicrobial therapy, indicating possible catheter‑related thrombotic infection 11.
• Diagnosis requires both a positive blood culture and imaging evidence of a thrombus (e.g., CT or ultrasound) 11.
• Treatment of septic thrombophlebitis mandates a minimum of 3–4 weeks of antimicrobial therapy 11.

Outcomes and Mortality

• A. baumannii bacteremia is associated with high mortality, and inappropriate or delayed therapy markedly increases the risk of death 8.

Note: All statements are derived from cited clinical evidence; specific guideline societies were not identified in the source material.